Novartis’ Alcon introduces new CyPass Ultra System

17 April 2018 (Last Updated April 17th, 2018 10:55)

Novartis’ subsidiary Alcon has introduced its new CyPass Ultra System for the optimised loading of a microinvasive glaucoma surgery (MIGS) device called CyPass Micro-Stent.

Novartis’ Alcon introduces new CyPass Ultra System
Alcon in Freiburg, Germany. Credit: Gerd Fahrenhorst.

Novartis’ subsidiary Alcon has introduced its new CyPass Ultra System for optimised loading of a microinvasive glaucoma surgery (MIGS) device called CyPass Micro-Stent.

The new product is intended to minimise the steps involved in CyPass Micro-Stent implantation in order to ensure safe, consistent yet long-term intraocular pressure (IOP) control.

CyPass Micro-Stent is designed to decrease IOP in mild-to-moderate primary open-angle glaucoma patients who have been referred for cataract surgery.

The new Ultra System features a loader tip, which contains a pre-loaded CyPass Micro-Stent, attached to a handheld surgical device called the CyPass applier.

“The new product is intended to minimise the steps involved in CyPass Micro-Stent implantation in order to ensure safe, consistent yet long-term intraocular pressure (IOP) control.”

Alcon North America region president Sergio Duplan said: “The introduction of the new CyPass Ultra System shows our commitment to partner with surgeons and continuously innovate in the surgical glaucoma space to ensure our technology delivers the best surgical experience possible.

“This new pre-loaded system makes it easier for surgeons to deliver optimal outcomes for their glaucoma patients undergoing cataract surgery.”

Alcon assessed the use of CyPass Micro-Stent in conjunction with cataract surgery during a randomised, multi-centre clinical trial, compared to cataract surgery alone in 100 subjects.

Results demonstrated a long-term decrease in IOP and minimal effects on refractive outcomes.

The most common postoperative adverse events observed during the trial were best corrected visual acuity (BCVA), loss of ten or more letters, anterior chamber cell and flare, corneal oedema and increase in IOP of ten or more mmHg.

Approved by the US Food and Drug Administration (FDA) in 2016, the stent is expected to be commercially launched in May this year.